{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:30:55Z","timestamp":1787239855828,"version":"build-2736575974"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:sec id=\"ab-eoi260035-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Ocular hypertension (OHT) is a primary risk factor for primary open-angle glaucoma (POAG), and systemic nicotinamide has emerged as a potential metabolic prophylactic intervention to prevent conversion; however, real-world evidence is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260035-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine whether systemic nicotinamide supplementation, with potential neuroprotective properties, is associated with reduced risk of POAG diagnosis and delayed need for medical or surgical escalation in patients with OHT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260035-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This cohort study evaluated deidentified electronic medical record data from a federated research network of 67 US health care organizations between March 2006 and March 2026. Nicotinamide supplementation was the sole exposure of interest and was specified a priori. Propensity score matching (1:1) was used to balance baseline covariates. Patients with a primary diagnosis of OHT and at least 1 prior health care encounter were included, excluding those with history of open-angle glaucoma, laser therapy, or glaucoma topical therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260035-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Documented systemic nicotinamide exposure, compared with a control group having no history of nicotinamide or niacin use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260035-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was risk of POAG diagnosis. Secondary outcomes included initiation of first-line topical glaucoma therapy and requirement for laser trabeculoplasty. Hazard ratios (HRs) and 95% CIs were estimated using time-to-event analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260035-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The propensity score-matched sample included 2920 patients (1460 in each cohort; nicotinamide group: mean [SD] age, 54.4 [19.6] years, 846 [57.9%] female; control group: mean [SD] age, 54.9 [18.8] years, 869 [59.5%] female). Over a mean (SD) follow-up of 3.7 (1.7) years, POAG diagnosis occurred in 51 patients in the nicotinamide group (3.5%) compared with 132 patients in the control group (9.0%) (HR, 0.34; 95% CI, 0.25-0.47;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001), representing an absolute risk reduction of 5.5% in the nicotinamide cohort (95% CI, 3.8-7.3). Topical intraocular pressure\u2013lowering therapy was initiated in 198 patients in the nicotinamide group (13.6%) compared with 309 patients in the control group (21.2%) (HR, 0.57; 95% CI, 0.48-0.68;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). Laser trabeculoplasty was performed in 12 patients in the nicotinamide group (0.8%) vs 28 patients (1.9%) in the control group (HR, 0.38; 95% CI, 0.19-0.74;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260035-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this cohort study, systemic nicotinamide exposure was associated with a reduced risk of disease development in patients with OHT. By potentially delaying POAG diagnosis and decreasing the rate of subsequent prescribed interventions, nicotinamide represents a potential adjunctive strategy complementary to standard therapy, warranting further prospective investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2026.2472","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:00:29Z","timestamp":1783609229000},"page":"724","source":"Crossref","is-referenced-by-count":1,"title":["Nicotinamide Supplementation and Primary Open-Angle Glaucoma in Patients With Ocular Hypertension"],"prefix":"10.1001","volume":"144","author":[{"given":"Jawad","family":"Muayad","sequence":"first","affiliation":[{"name":"College of Medicine, Texas A&M University, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed B.","family":"Sallam","sequence":"additional","affiliation":[{"name":"Bernice and Harvey Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock"},{"name":"Department of Ophthalmology, Faculty of Medicine, Ain Shams University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ticiana","family":"De Francesco","sequence":"additional","affiliation":[{"name":"Clinica de Olhos De Francesco, Fortaleza, Brazil"},{"name":"Hospital de Olhos Leiria de Andrade, Fortaleza, Brazil"},{"name":"John A. Moran Eye Center, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Gustavo","family":"De Moraes","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqbal Ike K.","family":"Ahmed","sequence":"additional","affiliation":[{"name":"John A. Moran Eye Center, University of Utah, Salt Lake City"},{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada"},{"name":"Prism Eye Institute, Mississauga, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"eoi260035r1","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/IJG.0000000000000767","article-title":"Glaucoma as a metabolic optic neuropathy: making the case for nicotinamide treatment in glaucoma.","volume":"26","author":"Williams","year":"2017","journal-title":"J Glaucoma"},{"issue":"7","key":"eoi260035r2","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1167\/iovs.19-27099","article-title":"Nicotinamide deficiency in primary open-angle glaucoma.","volume":"60","author":"Kouassi Nzoughet","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"eoi260035r3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13063-021-05968-1","article-title":"Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-controlled trial.","volume":"23","author":"Leung","year":"2022","journal-title":"Trials"},{"issue":"1","key":"eoi260035r4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1001\/jamaophthalmol.2021.4576","article-title":"Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial.","volume":"140","author":"De Moraes","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"eoi260035r5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ogla.2025.01.002","article-title":"American Glaucoma Society-American Academy of Ophthalmology position statement on nicotinamide use for glaucoma neuroprotection.","volume":"8","author":"Shukla","year":"2025","journal-title":"Ophthalmol Glaucoma"},{"issue":"5","key":"eoi260035r6","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/jid.2011.459","article-title":"Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials.","volume":"132","author":"Surjana","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"11","key":"eoi260035r7","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1001\/jamaophthalmol.2024.3884","article-title":"Prevalence of glaucoma among US adults in 2022.","volume":"142","author":"Ehrlich","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"6326","key":"eoi260035r8","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1126\/science.aal0092","article-title":"Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.","volume":"355","author":"Williams","year":"2017","journal-title":"Science"},{"key":"eoi260035r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100881","article-title":"Retinal energy metabolism in health and glaucoma.","volume":"81","author":"Casson","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"eoi260035r10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3389\/fnins.2017.00232","article-title":"Nicotinamide and WLDS act together to prevent neurodegeneration in glaucoma.","volume":"11","author":"Williams","year":"2017","journal-title":"Front Neurosci"},{"issue":"7","key":"eoi260035r11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/ceo.13818","article-title":"Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: a crossover randomized clinical trial.","volume":"48","author":"Hui","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"eoi260035r12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/bjo-2025-328096","article-title":"Effects of nicotinamide supplementation in normal-tension glaucoma: a crossover placebo-controlled randomised clinical trial.","volume":"110","author":"Ha","year":"2025","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"eoi260035r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaophthalmol.2021.0341","article-title":"Assessment of cumulative incidence and severity of primary open-angle glaucoma among participants in the Ocular Hypertension Treatment Study after 20 years of follow-up.","volume":"139","author":"Kass","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"eoi260035r14","doi-asserted-by":"publisher","first-page":"xxiv","DOI":"10.1016\/j.ajo.2018.02.016","article-title":"What we have learned from the ocular hypertension treatment study.","volume":"189","author":"Gordon","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"eoi260035r15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/biom10050687","article-title":"Possible adverse effects of high-dose nicotinamide: mechanisms and safety assessment.","volume":"10","author":"Hwang","year":"2020","journal-title":"Biomolecules"},{"issue":"8","key":"eoi260035r16","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1097\/IJG.0000000000002394","article-title":"Drug-induced liver injury during a glaucoma neuroprotection clinical trial.","volume":"33","author":"Shukla","year":"2024","journal-title":"J Glaucoma"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2850835\/jamaophthalmology_muayad_2026_oi_260035_1787172278.15117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:01:58Z","timestamp":1787238118000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2850835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2026.2472","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}